Revance Therapeutics, INC
Market Movers (8-K)
Crown Laboratories finalizes its acquisition of Revance Therapeutics, reinforcing its position in the aesthetics and skincare market.
Revance Therapeutics has agreed to a revised acquisition offer from Crown Laboratories, increasing the offer price to $3.65 per share and extending the tender offer deadline to February 4, 2025.
Better than expected
Delay expected
Revance Therapeutics has amended its merger agreement with Crown Laboratories to clarify the calculation of the Expiration Time.
Crown Laboratories will launch a tender offer to acquire Revance Therapeutics for $3.10 per share in cash, following an amended merger agreement.
Worse than expected
Revance Therapeutics and Crown Laboratories have agreed to a further extension of the deadline for Crown to commence its tender offer for Revance shares, now set for December 9, 2024.
Worse than expected
Delay expected
Revance Therapeutics has received approval in China for its cervical dystonia treatment and has further extended the tender offer commencement date to December 5, 2024.
Worse than expected
Delay expected
Quarterly Earnings (10-Q)
Revance Therapeutics announced its Q3 2024 financial results, highlighting product revenue growth and strategic shifts, while navigating a pending merger and ongoing operational adjustments.
Worse than expected
Delay expected
Capital raise
Revance Therapeutics reports a net loss of $37.5 million for the second quarter of 2024, with revenue growth driven by increased sales of DAXXIFY and RHA dermal fillers.
Worse than expected
Capital raise
Revance Therapeutics reports a net loss of $53.2 million for Q1 2024, while seeing a 13% increase in product revenue compared to the same period last year.
Worse than expected
Capital raise
Annual Reports (10-K)
Revance Therapeutics' 10-K filing highlights a year of commercial expansion, strategic shifts, and continued investment in its aesthetics and therapeutics portfolio, while also detailing financial performance and future outlook.
Capital raise
Worse than expected
Insider Trading (Form 4)
Director Julian S Gangolli reports the disposal of Revance Therapeutics shares and restricted stock awards following the completion of a merger with Crown Laboratories.
Form 4: Revance Therapeutics President & CEO Foley Disposes of Shares in Merger with Crown Laboratories
Mark J. Foley, President & CEO of Revance Therapeutics, reports the disposition of shares and restricted stock units following the merger agreement with Crown Laboratories.
CFO Tobin Schilke reports the disposal of Revance Therapeutics shares and restricted stock units (RSUs) following the merger agreement with Crown Laboratories.
Form 4: Revance Therapeutics CLO & GC, Dwight Moxie, Reports Beneficial Ownership Changes Following Merger
Dwight Moxie, CLO & GC of Revance Therapeutics, reports changes in beneficial ownership due to the merger with Crown Laboratories, including the tendering of shares and cancellation of restricted stock units and performance-based restricted stock units.
Following the completion of a merger with Crown Laboratories, Revance Therapeutics' CMO David Hollander reports the disposal of common stock and cancellation of restricted stock units.
Erica Jordan, Chief Commercial Officer of Revance Therapeutics, disposes of shares and restricted stock units following the completion of a merger with Crown Laboratories.
Proxy Statements (Def-14A)
Revance Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
DEF 14A: Revance Therapeutics Aims for Growth in Aesthetics and Therapeutics Markets Following FDA Approval
Revance Therapeutics outlines its strategic priorities for 2024, focusing on expanding its aesthetics portfolio and entering the therapeutics market with DAXXIFY.
Capital raise